PE20160932A1 - Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida - Google Patents
Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamidaInfo
- Publication number
- PE20160932A1 PE20160932A1 PE2016000711A PE2016000711A PE20160932A1 PE 20160932 A1 PE20160932 A1 PE 20160932A1 PE 2016000711 A PE2016000711 A PE 2016000711A PE 2016000711 A PE2016000711 A PE 2016000711A PE 20160932 A1 PE20160932 A1 PE 20160932A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- azetidin
- octahydro
- piperazin
- dioxo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- -1 4-HYDROXYPHENYL Chemical class 0.000 title 1
- MHZGAVWIXHVIET-UHFFFAOYSA-N N1(NC=NC=C1)C(=O)N Chemical compound N1(NC=NC=C1)C(=O)N MHZGAVWIXHVIET-UHFFFAOYSA-N 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- ZGNKNLOBYFTGRG-GIWKVKTRSA-N (6S,9aS)-N-benzyl-8-[[6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl]methyl]-6-[(2-fluoro-4-hydroxyphenyl)methyl]-4,7-dioxo-2-prop-2-enyl-3,6,9,9a-tetrahydropyrazino[2,1-c][1,2,4]triazine-1-carboxamide Chemical compound C1CN(CC)CCN1C1CN(C=2N=C(CN3C([C@H](CC=4C(=CC(O)=CC=4)F)N4[C@@H](N(N(CC=C)CC4=O)C(=O)NCC=4C=CC=CC=4)C3)=O)C=CC=2)C1 ZGNKNLOBYFTGRG-GIWKVKTRSA-N 0.000 abstract 1
- SNDNPPITFPXTTR-GIWKVKTRSA-N (6S,9aS)-N-benzyl-8-[[6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl]methyl]-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-2-prop-2-enyl-3,6,9,9a-tetrahydropyrazino[2,1-c][1,2,4]triazine-1-carboxamide Chemical compound C(C1=CC=CC=C1)NC(=O)N1N(CC(N2[C@@H]1CN(C([C@@H]2CC2=CC=C(C=C2)O)=O)CC2=NC(=CC=C2)N2CC(C2)N2CCN(CC2)CC)=O)CC=C SNDNPPITFPXTTR-GIWKVKTRSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invencion se refiere a compuestos de formula (I) que tiene actividad de modulacion de la via Wnt para tratamiento de cancer. Donde: R1 es alquiloC1-6; R2 y R3 son H o alquilo C1-6; X2, X3 y X4 son H o halogeno y X5 es H o P(=O)(OH)2. Son compuestos preferidos: (6S, 9aS) N- bencil -8-((6-(3-(4-etil-piperazin-1-il) azetidin-1-il)piridin-2-il)metil)-6-((2-fluoro-4-hidroxfenil)metil)-4,7-dioxo-2- (prop-2-en-1-il) - octahidro -1H- pirazino[2,1-c][1,2,4] triazina-1-carboxamida; (6S,9aS) -N- bencil-8 -((6- (3- (4-etil-piperazin-1-il)azetidin-1-il)piridin-2-il)metil)-6 -((4- hidroxifenil)metil)-4,7-dioxo-2-(prop-2-en-1-il) - octahidro -1H-pirazino[2,1-c][1,2,4] triazina-1-carboxamida; entre otros
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013267687 | 2013-12-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20160932A1 true PE20160932A1 (es) | 2016-09-10 |
Family
ID=53399298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016000711A PE20160932A1 (es) | 2013-12-25 | 2014-12-22 | Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida |
Country Status (34)
Country | Link |
---|---|
US (1) | US9174998B2 (es) |
EP (1) | EP3088401B1 (es) |
JP (1) | JP6085040B2 (es) |
KR (1) | KR102307053B1 (es) |
CN (1) | CN105873932B (es) |
AR (1) | AR098908A1 (es) |
AU (1) | AU2014371148B2 (es) |
BR (1) | BR112016013572B1 (es) |
CA (1) | CA2932435C (es) |
CL (1) | CL2016001419A1 (es) |
CY (1) | CY1122521T1 (es) |
DK (1) | DK3088401T3 (es) |
ES (1) | ES2728353T3 (es) |
HK (1) | HK1222656A1 (es) |
HR (1) | HRP20190908T1 (es) |
HU (1) | HUE044541T2 (es) |
IL (1) | IL245961A0 (es) |
JO (1) | JO3809B1 (es) |
LT (1) | LT3088401T (es) |
ME (1) | ME03391B (es) |
MX (1) | MX365376B (es) |
MY (1) | MY173946A (es) |
PE (1) | PE20160932A1 (es) |
PH (1) | PH12016501079A1 (es) |
PL (1) | PL3088401T3 (es) |
PT (1) | PT3088401T (es) |
RS (1) | RS58955B1 (es) |
RU (1) | RU2669805C2 (es) |
SG (1) | SG11201604496YA (es) |
SI (1) | SI3088401T1 (es) |
TR (1) | TR201908392T4 (es) |
TW (1) | TWI681961B (es) |
UA (1) | UA116923C2 (es) |
WO (1) | WO2015098853A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
PL3524595T3 (pl) | 2014-08-28 | 2022-10-31 | Eisai R&D Management Co., Ltd. | Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania |
HUE064614T2 (hu) | 2015-02-25 | 2024-04-28 | Eisai R&D Man Co Ltd | Eljárás egy kinolin-származék keserû ízének elnyomására |
KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
BR112017027227B1 (pt) * | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
CA2986999C (en) | 2015-06-23 | 2023-08-08 | Eisai R&D Management Co., Ltd. | Crystal of (6s,9as)-n-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h)-carboxamide |
CN108084067B (zh) * | 2016-11-22 | 2019-08-30 | 重庆圣华曦药业股份有限公司 | 一种立他司特中间体的制备方法 |
CN110072528B (zh) | 2017-02-08 | 2022-04-26 | 卫材R&D管理有限公司 | 治疗肿瘤的药物组合物 |
US20220409724A1 (en) | 2019-10-29 | 2022-12-29 | Eisai R&D Management Co., Ltd. | Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer |
US11655253B2 (en) | 2020-03-12 | 2023-05-23 | 3+2 Pharma, Llc | CBP/catenin signaling pathway inhibitors and uses thereof |
WO2022092294A1 (ja) | 2020-10-30 | 2022-05-05 | 学校法人慶應義塾 | サルコペニア関連疾患等の新規治療および予防 |
WO2023027888A1 (en) * | 2021-08-26 | 2023-03-02 | 3+2 Pharma, Llc | Pyrazole-containing cbp/catenin antagonists and uses thereof |
CA3227813A1 (en) | 2021-09-08 | 2023-03-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating solid tumors |
WO2023140369A1 (en) * | 2022-01-18 | 2023-07-27 | Prism BioLab Co., Ltd. | Phosphoric acid derivatives |
WO2023190748A1 (ja) * | 2022-03-31 | 2023-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
CN115784934A (zh) * | 2022-11-22 | 2023-03-14 | 上海吉奉生物科技有限公司 | 一种酪氨酸衍生物的合成方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8080657B2 (en) | 2001-10-12 | 2011-12-20 | Choongwae Pharma Corporation | Compounds of reverse turn mimetics and the use thereof |
US7671054B1 (en) * | 2001-10-12 | 2010-03-02 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
ATE398129T1 (de) * | 2001-10-12 | 2008-07-15 | Choongwae Pharma Corp | Reverse-turn-mimetika und diese betreffendes verfahren |
JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
RU2512538C2 (ru) | 2008-06-06 | 2014-04-10 | Присм Байолэб Корпорейшн | Альфа-спиральные миметики и способы, связанные с ними |
SG175045A1 (en) * | 2009-04-15 | 2011-11-28 | Jw Pharmaceutical Corp | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
WO2012050393A2 (ko) * | 2010-10-14 | 2012-04-19 | 제이더블유중외제약 주식회사 | 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도 |
CN103517904A (zh) * | 2011-02-25 | 2014-01-15 | 株式会社棱镜制药 | α-螺旋模拟物和与其相关的方法 |
-
2014
- 2014-12-19 US US14/577,660 patent/US9174998B2/en active Active
- 2014-12-21 JO JOP/2014/0373A patent/JO3809B1/ar active
- 2014-12-22 WO PCT/JP2014/083932 patent/WO2015098853A1/ja active Application Filing
- 2014-12-22 AU AU2014371148A patent/AU2014371148B2/en active Active
- 2014-12-22 PL PL14873998T patent/PL3088401T3/pl unknown
- 2014-12-22 BR BR112016013572-5A patent/BR112016013572B1/pt active IP Right Grant
- 2014-12-22 PT PT14873998T patent/PT3088401T/pt unknown
- 2014-12-22 SI SI201431226T patent/SI3088401T1/sl unknown
- 2014-12-22 UA UAA201606261A patent/UA116923C2/uk unknown
- 2014-12-22 ME MEP-2019-158A patent/ME03391B/me unknown
- 2014-12-22 MY MYPI2016702025A patent/MY173946A/en unknown
- 2014-12-22 SG SG11201604496YA patent/SG11201604496YA/en unknown
- 2014-12-22 HU HUE14873998 patent/HUE044541T2/hu unknown
- 2014-12-22 RU RU2016122867A patent/RU2669805C2/ru active
- 2014-12-22 MX MX2016007705A patent/MX365376B/es active IP Right Grant
- 2014-12-22 CN CN201480067017.7A patent/CN105873932B/zh active Active
- 2014-12-22 AR ARP140104850A patent/AR098908A1/es active IP Right Grant
- 2014-12-22 KR KR1020167015608A patent/KR102307053B1/ko active IP Right Grant
- 2014-12-22 RS RS20190665A patent/RS58955B1/sr unknown
- 2014-12-22 JP JP2015554886A patent/JP6085040B2/ja active Active
- 2014-12-22 TR TR2019/08392T patent/TR201908392T4/tr unknown
- 2014-12-22 ES ES14873998T patent/ES2728353T3/es active Active
- 2014-12-22 EP EP14873998.0A patent/EP3088401B1/en active Active
- 2014-12-22 DK DK14873998.0T patent/DK3088401T3/da active
- 2014-12-22 PE PE2016000711A patent/PE20160932A1/es unknown
- 2014-12-22 LT LTEP14873998.0T patent/LT3088401T/lt unknown
- 2014-12-22 CA CA2932435A patent/CA2932435C/en active Active
- 2014-12-22 TW TW103144928A patent/TWI681961B/zh active
-
2016
- 2016-06-01 IL IL245961A patent/IL245961A0/en active IP Right Grant
- 2016-06-07 PH PH12016501079A patent/PH12016501079A1/en unknown
- 2016-06-09 CL CL2016001419A patent/CL2016001419A1/es unknown
- 2016-09-13 HK HK16110848.5A patent/HK1222656A1/zh unknown
-
2019
- 2019-05-16 HR HRP20190908TT patent/HRP20190908T1/hr unknown
- 2019-05-31 CY CY20191100578T patent/CY1122521T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20160932A1 (es) | Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida | |
PH12019501321B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders | |
PH12015501058A1 (en) | Pyrimidine-2,4-diamine derivatives for treatment of cancer | |
PH12015502036A1 (en) | Inhibitors of the kynurenine pathway | |
MX2016001011A (es) | Derivados de quinazolin-4-ona sustituida. | |
NI201300113A (es) | Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y métodos de tratamiento con las mismas. | |
BR112014005226A2 (pt) | derivados de benzonitrila como inibidores de cinase | |
MX2015010125A (es) | Derivados de piridazinona-amidas. | |
PE20150734A1 (es) | Inhibidores de glucosilceramida sintasa | |
PH12015501363A1 (en) | Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity | |
MX2015001720A (es) | Hetero-azepinonas sustituidas. | |
UY34451A (es) | Derivados de uracilo como inhibidores de la quinasa axl y c-met | |
NI201500140A (es) | Compuestos y composiciones terapéuticos | |
CR20140537A (es) | Compuesto heterocíclico nitrogenado | |
BR112015021524A2 (pt) | derivados de sulfonil quinolina e usos dos mesmos | |
BR112015019276A2 (pt) | compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios | |
MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
MA38884A1 (fr) | Composé de triazolopyridine, compositions et procédés d'utilisation associés | |
PH12016500735A1 (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
AR092772A1 (es) | Derivado de 7-azaindol | |
NZ707087A (en) | Novel flavonoid compounds and uses thereof | |
CU20150048A7 (es) | Compuestos heteroaromáticos como ligandos d1 de dopamina | |
AR096310A1 (es) | Compuestos de 3,4-dihidroisoquinolin-2(1h)-ilo | |
NZ709094A (en) | Pyrimidine-2,4-diamine derivatives for treatment of cancer | |
UA63814U (ru) | Применение 4-[4-оксо-3(4н)-хиназолин]бензойной кислоты в качестве средства, которое стимулирует венечный кровоток |